Zevra Therapeutics, Inc.ZVRANASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, structural decline.
Left:
||||
Year-over-year research & development expense growth
Latest
5.75%
↓ 79% below average
Average (9y)
27.58%
Historical baseline
Range
High:102.78%
Low:-54.45%
CAGR
-11.3%
Structural decline
| Period | Value |
|---|---|
| 2024 | 5.75% |
| 2023 | 101.01% |
| 2022 | 94.89% |
| 2021 | 14.90% |
| 2020 | -54.45% |
| 2019 | -53.51% |
| 2018 | 102.78% |
| 2017 | 0.59% |
| 2016 | 46.95% |
| 2015 | 16.90% |